Topol departs Cleveland Clinic

Eric Topol, an outspoken critic of COX-2 inhibitors and a witness in Vioxx product liability cases, resigns from his position as chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic. Topol will join the Department of Genetics at Case Western University. He will continue to work with the Cleveland Clinic as a consultant and serve as program director of an NIH grant in collaboration with the clinic. A study of Pfizer's COX-2 Celebrex will be conducted at the Cleveland Clinic under the direction of Steven Nissen (1"The Pink Sheet" Dec. 19, 2005, p. 18)...

Eric Topol, an outspoken critic of COX-2 inhibitors and a witness in Vioxx product liability cases, resigns from his position as chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic. Topol will join the Department of Genetics at Case Western University. He will continue to work with the Cleveland Clinic as a consultant and serve as program director of an NIH grant in collaboration with the clinic. A study of Pfizer's COX-2 Celebrex will be conducted at the Cleveland Clinic under the direction of Steven Nissen (¹ (Also see "Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study" - Pink Sheet, 19 Dec, 2005.), p. 18)....